Ep. 46 -Evaluating High Cost Diabetes Therapies with Henry So, Pharm.D., BCACP, BCPS

On this episode, we welcome back Henry So, clinical pharmacist for Diamond's OPTICS team. As we recorded this, Henry was days away from giving an NCCHC conference presentation on evaluating high cost therapies for type 2 diabetes patients. We discuss why he was inspired to develop a presentation around this topic, look at the use of different diabetic agents in special patient populations, and dive into his clinical rationale for helping providers choose between newer often pricier agents and older more established therapies. If you missed Henry’s presentation at NCCHC, you can catch up with this podcast. Links to studies mentioned in the show/futher reading: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | New England Journal of Medicine Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | New England Journal of Medicine Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | New England Journal of Medicine Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine Empagliflozin in Heart Failure with a Preserved Ejection Fraction | New England Journal of Medicine Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | New England Journal of Medicine Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | New England Journal of Medicine Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | New England Journal of Medicine Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial - PubMed (nih.gov) Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics - PubMed (nih.gov)